The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Hengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
Mechanisms of cytochrome c release from mitochondria
Garrido, C., Galluzzi, L., Brunet, M., Puig, P. E., Didelot, C., & Kroemer, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401950 · Cited by 1,390
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Self-citationAntitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Self-citationRademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Self-citationMetal-based antitumour drugs in the post genomic era
Dyson, P. J., & Sava, G. (2006) · Dalton Transactions · doi:10.1039/b601840h · Cited by 771
Self-citationNew roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?
Coqueret, O. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)00043-0 · Cited by 751
Role of JNK activation in apoptosis: A double-edged sword
LIU, J., & LIN, A. (2005) · Cell Research · doi:10.1038/sj.cr.7290262 · Cited by 738
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Self-citationAird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Allardyce, C. S., Dyson, P. J., Ellis, D. J., & Heath, S. L. (2001) · Chemical Communications · doi:10.1039/b104021a · Cited by 495
Self-citationTGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
Seoane, J., Pouponnot, C., Staller, P., Schader, M., Eilers, M., & Massagué, J. (2001) · Nature Cell Biology · doi:10.1038/35070086 · Cited by 489
JNK targets p53 ubiquitination and degradation in nonstressed cells
Fuchs, S. Y., Adler, V., Buschmann, T., Yin, Z., Wu, X., Jones, S. N., & Ronai, Z. (1998) · Genes & Development · doi:10.1101/gad.12.17.2658 · Cited by 341
The mechanism of action of platinum antitumor drugs
Reedijk, J. (1987) · Pure and Applied Chemistry · doi:10.1351/pac198759020181 · Cited by 277
Pongratz, M., Schluga, P., Jakupec, M. A., Arion, V. B., Hartinger, C. G., Allmaier, G., & Keppler, B. K. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b309160k · Cited by 206
Self-citationThe binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
Kratz, F., Hartmann, M., Keppler, B., & Messori, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41984-3 · Cited by 204
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Kuo, P.-C., Liu, H.-F., & Chao, J.-I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407985200 · Cited by 190
Jakupec, M. A., Reisner, E., Eichinger, A., Pongratz, M., Arion, V. B., Galanski, M. S., Hartinger, C. G., & Keppler, B. K. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0490742 · Cited by 164
Self-citationInfluence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds
Scolaro, C., Geldbach, T. J., Rochat, S., Dorcier, A., Gossens, C., Bergamo, A., Cocchietto, M., Tavernelli, I., Sava, G., Röthlisberger, U., et al. (2005) · Organometallics · doi:10.1021/om0508841 · Cited by 157
Self-citationGaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089342 · Cited by 142
Ruthenium-based compounds and tumour growth control (review).
Sava, G., & Bergamo, A. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.2.353 · Cited by 118
Połeć, K., Abramski, J. K., Semenova, O. P., Hartinger, C. G., Timerbaev, A. R., Keppler, B. K., & Jarosz, M. (2006) · Electrophoresis · doi:10.1002/elps.200500694 · Cited by 105
Self-citationHayward, R. L., Schornagel, Q. C., Tente, R., Macpherson, J. S., Aird, R. E., Guichard, S. M., Habtemariam, A., Sadler, P. J., & Jodrell, D. I. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0932-9 · Cited by 95
Piccioli, F., Sabatini, S., Luigi Messori, A., Orioli, P., Hartinger, C. G., & Keppler, B. K. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.002 · Cited by 83
Self-citationBundy, L. M., Wells, S., & Sealy, L. J. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-43 · Cited by 81
Zu, K., Hawthorn, L., & Ip, C. C. Y. (2005) · PubMed · Cited by 65
Ishikawa, Y., Kusaka, E., Enokido, Y., Ikeuchi, T., & Hatanaka, H. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00203-3 · Cited by 59
Yoshida, K., & Miki, Y. (2005) · Cell Cycle · doi:10.4161/cc.4.6.1746 · Cited by 53
Senescence-like changes induced by expression of p21Waf1/Cip1 in NIH3T3 cell line
Chen, X., Zhang, W., Gao, Y., Su, X., & Zhai, Z. H. (2002) · Cell Research · doi:10.1038/sj.cr.7290129 · Cited by 53
Choi, J., Chiang, A., Taulier, N., Gros, R., Pirani, A., & Husain, M. (2006) · Circulation Research · doi:10.1161/01.res.0000223059.19250.91 · Cited by 50
Jaiswal, A. S., Bloom, L. B., & Narayan, S. (2002) · Oncogene · doi:10.1038/sj.onc.1205789 · Cited by 48
Perrone, G., Vincenzi, B., Santini, D., Verzì, A., Tonini, G., Vetrani, A., & Rabitti, C. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.11.032 · Cited by 43
Cited by
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
van Rijt, S. H., & Sadler, P. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.003 · Cited by 592
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
Metadata
- Authors
- Chatterjee, S., Kundu, S., Bhattacharyya, A., Hartinger, C. G., & Dyson, P. J.
- Venue
- JBIC Journal of Biological Inorganic Chemistry
- Published
- 2008-07-03
- Volume
- 13
- Issue
- 7
- Pages
- 1149-1155
- ISSN
- 0949-8257 (ISSN-L)
- 1432-1327
- OpenAlex
- W2042390732
- Cited by
- 258
- References
- 39
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.